Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy

Zhenfei Li, Mohammad Alyamani, Jianneng Li, Kevin Rogacki, Mohamed Abazeed, Sunil K. Upadhyay, Steven P. Balk, Mary-Ellen Taplin, Richard J. Auchus and Nima Sharifi ()
Additional contact information
Zhenfei Li: Lerner Research Institute, Cleveland Clinic
Mohammad Alyamani: Lerner Research Institute, Cleveland Clinic
Jianneng Li: Lerner Research Institute, Cleveland Clinic
Kevin Rogacki: Taussig Cancer Institute, Cleveland Clinic
Mohamed Abazeed: Taussig Cancer Institute, Cleveland Clinic
Sunil K. Upadhyay: University of Michigan Medical School
Steven P. Balk: Beth Israel Deaconess Medical Center, Harvard Medical School
Mary-Ellen Taplin: Dana-Farber Cancer Institute, Harvard Medical School
Richard J. Auchus: University of Michigan Medical School
Nima Sharifi: Lerner Research Institute, Cleveland Clinic

Nature, 2016, vol. 533, issue 7604, 547-551

Abstract: The prostate cancer drug abiraterone can be metabolized into several substances with different effects, and optimization of this process could be helpful for fine-tuning the treatment of prostate cancer.

Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature17954 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:533:y:2016:i:7604:d:10.1038_nature17954

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature17954

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().